Aquinox Pharmaceuticals Inc. plans to stop developing its main drug to treat bladder pain syndrome as rosiptor failed to meet the main goal of a late-stage trial, pushing the company’s shares down as much as 85 percent.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
It’s not hard to see how precision medicine will re-make the world of research and development and manufacturing and distribution for pharmaceutical and medical product companies. But it will make new demands on the supply chains of these organizations.
AstraZeneca’s oncology business received a boost as results of a clinical trial showed the company’s drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.
Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent with similar tumors who received standard therapies.
A combination of Pfizer’s breast cancer medicine Ibrance and another drug was not statistically significant in extending overall survival in certain patients, the secondary goal of a late-stage trial.
Eli Lilly and Co.’s Jardiance, along with insulin therapy, met the main goal of two trials testing the company’s drug in patients with type 1 diabetes.
Merrimack Pharmaceuticals Inc. will stop developing the company’s experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.
A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.
Growth in fibromyalgia drug research over the past five years has made site selection a far less taxing prospect. There are now hundreds of sites capable of performing this research, and the challenge is to gather current feedback on them.
UroGen Pharma plans to begin a mid-stage trial of the company’s treatment for bladder cancer patients after positive interim results from an advanced trial of a treatment for upper urinary tract cancer.
Sanofi hired John Reed, the former top scientist at oncology market leader Roche, to head the drugmaker’s group research operations.
Anika Therapeutics Inc. announced results from the company’s CINGAL 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration.
Sarepta Therapeutics shares jumped 60 percent after reporting promising results from an early-stage study testing its gene therapy in patients with Duchenne muscular dystrophy (DMD).
Valeant Pharmaceuticals International Inc.’s plaque psoriasis treatment did not get approval from U.S. health regulators.
Teva Pharmaceutical Inc. will discontinue a trial testing the company’s drug for the treatment of chronic cluster headache.
AIDS researchers in Hong Kong say new research – tested on mice – indicates a functional cure for HIV, eventually leading to a new antibody that could be used for prevention and treatment.
Novartis touted safety and efficacy of the company’s biosimilar copies of Johnson & Johnson’s Remicade and Amgen’s Enbrel for treating autoimmune diseases.
GlaxoSmithKline’s two-drug treatment for HIV met its main goal in late-stage studies, scoring key points in the company’s rivalry with Gilead in the medical field.
Eli Lilly and Co. said the company’s drug to treat the autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a larger study in 2018.
Boston-based Flex Pharma announced the closing of a Phase II clinical trial of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).
Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.